login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

Phenox receives CE mark approval for pCONus Bifurcation Aneurysm Implant


Friday, 11 Jan 2013 11:54
Phenox implant
Phenox implant

Phenox has announced that the pCONus Bifurcation Aneurysm Implant has been granted CE mark approval for commercialisation within the European Union and any country that accepts CE mark approval. The pCONus implant is a new category of intraluminal stent intended to treat complex, wide neck intracranial bifurcation aneurysms.


Hermann Monstadt, managing director at phenox, said: “phenox continues to expand its portfolio of easy to use innovative tools to help physicians treat patients with complex intracranial aneurysms that have unmet clinical needs. This approval adds support to our strategy of focusing on creative solutions for complex clinical problems.”

The pCONus implant is a new class of endoluminal device that is designed to support the mass of coils at the level of the neck of wide neck bifurcation aneurysms that cannot be easily coiled or surgically treated. It combines features of an endoluminal stent with an intra-aneurysmal implant.

According to the company, the implant features a distal end that opens like a blossoming flower and its petals rest on the inside of the aneurysm along the neck. The body of the implant is deployed in the parent artery and anchors the device securely in place. The device can be deployed completely and recovered completely for optimal, accurate and safe repositioning. When the operator is satisfied with its position the aneurysm is then coiled by passing a microcatheter inside the stent and through a nylon net at the base of the petals. Once the coiling is complete and the physician has removed the coiling microcatheter, the pCONus Implant is detached via an electrolytic detachment process.

According to Ralf Hannes, chief technical officer at phenox, “the pCONus implant offers a significant reduction in the amount of metal typically implanted in “Y stenting” technique. The design of the cells and the implant structure are such that there is less than 5% metal to artery surface coverage.”

Hans Henkes, Katharinenhospital, Stuttgart, Germany said: “the pCONus implant allows me to simplify my treatment strategy for these extremely complex lesions. The simplicity of the system allows me to focus on the coil occlusion rather than the multiple devices that otherwise would be required to protect the branches of the parent artery. It makes a very complex, difficult procedure extremely simple and safe.”

Phenox is planning to conduct a post market surveillance study of 100 patients in order to capture long term data for up to 24 months post treatment.




Add New Comment

Most popular


MR CLEAN: expert opinion
Tuesday, 18 Nov 2014
Since the first presentation of data at the World Stroke Congress, the MR CLEAN trial has sent a ripple across the entire neurointerventional arena, raising questions about the future of stroke ... MR CLEAN: expert opinion

First patient treated in US pivotal trial evaluating cerebral protection during TAVI
Thursday, 09 Oct 2014
The randomised controlled SENTINEL Trial is the first in the USA to study capture and removal of debris released during TAVI that may otherwise be the source of stroke. First patient treated in US pivotal trial evaluating cerebral protection during TAVI

New Envoy catheters launched
Saturday, 11 Oct 2014
Codman Neuro has announced the Europe, Middle East and Africa launch of the Envoy DA XB Distal Access Guiding Catheter and the 7F Envoy Guiding Catheter for neurovascular procedures. New Envoy catheters launched

Features


The changing face of traumatic brain injury: Life beyond the guidelines
Tuesday, 18 Nov 2014
András Büki and Andrew Maas write that despite considerable efforts both in basic and clinical research, there has not been a major breakthrough in the care of the head injured in the last three ... The changing face of traumatic brain injury: Life beyond the guidelines

Neuro-oncologic treatment for glioblastoma
Monday, 21 Jul 2014
Malignant gliomas are the most common type of primary malignant brain tumour, accounting for 80% of patients and an annual incidence of 5.26 per 100,000 population, or 17,000 new cases diagnosed per ... Neuro-oncologic treatment for glioblastoma

Profiles


Vladimír Beneš Jr
Tuesday, 30 Sep 2014
Vladimír Beneš Jr is professor and chair at the First Medical School, Charles University, P... Vladimír Beneš Jr

Mauricio Castillo
Monday, 14 Jul 2014
Mauricio Castillo is a professor of Radiology and chief, Division of Neuroradiology, University of N... Mauricio Castillo

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions